Isosteres of hydroxypyridinethione as drug-like pharmacophores for metalloenzyme inhibition
Hydroxypyridinethiones (HOPTOs) are strong ligands for metal ions and potentially useful pharmacophores for inhibiting metalloenzymes relevant to human disease. However, HOPTOs have been sparingly used in drug discovery efforts due, in part, to concerns that this scaffold will act as a promiscuous, non-selective metalloenzyme inhibitor, as well as possess poor pharmacokinetics (PK), which may undermine drug candidates containing this functional group. To advance HOPTOs as a useful pharmacophore for metalloenzyme inhibitors, a library of 22 HOPTO isostere compounds has been synthesized and investigated. This library demonstrates that it is possible to maintain the core metal-binding pharmacophore (MBP) while generating diversity in structure, electronics, and PK properties. This HOPTO library has been screened against a set of four different metalloenzymes, demonstrating that while the same metal-binding donor atoms are maintained, there is a wide range of activity between metalloenzyme targets. Overall, this work shows that HOPTO isosteres are useful MBPs and valuable scaffolds for metalloenzyme inhibitors.
KeywordsFragment-based drug discovery Hydroxypyridinethione Inhibitor Isostere Metal-binding pharmacophore Metalloenzyme
This work was supported by the National Institutes of General Medical Sciences (R01-GM111926). R.N.A. was supported by the National Institute of Health Chemical Biology Interfaces Training Grant UC San Diego (T32GM112584-01). We thank Prof. Arnold Rheingold and Dr. Curtis Moore (U.C. San Diego) for assistance with crystallographic data collection and structure determination. We also thank Dr. Yongxuan Su (U.C. San Diego) for mass spectrometry sample analysis at The Molecular Mass Spectrometry Facility. We thank Dr. Carlo Ballatore for aiding with Sirius PK analysis. We thank Dr. Yuyong Ma for preparing compound 11. S.M.C. is a co-founder, has an equity interest, and receives income as member of the Scientific Advisory Board for Cleave Biosciences and is a co-founder, has an equity interest, and a member of the Scientific Advisory Board for Forge Therapeutics. Both companies may potentially benefit from the research results of certain projects in the laboratory of S.M.C. The terms of this arrangement have been reviewed and approved by the University of California, San Diego, in accordance with its conflict of interest policies.
- 14.Summa V, Petrocchi A, Bonelli F, Crescenzi B, Donghi M, Ferrara M, Fiore F, Gardelli C, Paz OG, Hazuda DJ, Jones P, Kinzel O, Laufer R, Monteagudo E, Muraglia E, Nizi E, Orvieto F, Pace P, Pescatore G, Scarpelli R, Stillmock K, Witmer MV, Rowley M (2008) Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem 51:5843–5855CrossRefPubMedGoogle Scholar
- 15.Gunthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, Hoy JF, Mugavero MJ, Sax PE, Thompson MA, Gandhi RT, Landovitz RJ, Smith DM, Jacobsen DM, Volberding PA (2016) Antiretroviral drugs for treatment and prevention of HIV infection in adults 2016 recommendations of the international antiviral society-USA panel. Jama-J. Am. Med. Assoc. 316:191–210CrossRefGoogle Scholar
- 17.Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM (1992) Effect of captopril on mortality and morbidity in patients with left-ventricular dysfunction after myocardial-infarction—results of the survival and ventricular enlargement trial. New Engl. J. Med. 327:669–677CrossRefPubMedGoogle Scholar
- 24.Britten CD, Rowinsky EK, Soignet S, Patnaik A, Yao SL, Deutsch P, Lee Y, Lobell RB, Mazina KE, McCreery H, Pezzuli S, Spriggs D (2001) A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies. Clin Cancer Res 7:3894–3903PubMedGoogle Scholar
- 26.Jones, R. A.; Katritzky, A. R. N-oxides and related Compounds.17. The tautomerism of mercapto-pyridine and acylamino-pyridine 1-oxides. J. Chem. Soc. 1960, 2937–2942Google Scholar
- 39.Hughes JD, Blagg J, Price DA, Bailey S, DeCrescenzo GA, Devraj RV, Ellsworth E, Fobian YM, Gibbs ME, Gilles RW, Greene N, Huang E, Krieger-Burke T, Loesel J, Wager T, Whiteley L, Zhang Y (2008) Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett 18:4872–4875CrossRefPubMedGoogle Scholar